SAN DIEGO

圣迭戈

,

，

Aug. 13, 2026

2026年8月13日

/PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq:

/美通社/ -- Atrium Therapeutics, Inc.（纳斯达克：

RNA

核糖核酸

) ('Atrium,' 'Atrium Therapeutics' or the 'Company'), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE:

）（“Atrium”、“Atrium Therapeutics”或“公司”），一家致力于向心脏递送RNA疗法的生物制药公司，今日宣布已获得来自百时美施贵宝（纽约证券交易所：

BMY

BMY

) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's ongoing collaboration.

）基于在公司持续合作下，成功交付一种针对未公开心血管适应症的先导化合物。

'Atrium's vision is to deliver treatments that address the underlying cause of serious heart disease, including rare genetic cardiomyopathies,' said Kathleen Gallagher, President and CEO of Atrium Therapeutics. 'Advancing a second lead compound under our collaboration with Bristol Myers Squibb reflects the strength and versatility of our RNA delivery platform, and it gives us continued momentum as we work together to bring novel therapies to patients and families facing significant unmet need.'.

“Atrium Therapeutics 的愿景是提供能够解决严重心脏病根本病因的治疗方案，包括罕见的遗传性心肌病，”Atrium Therapeutics 总裁兼首席执行官凯瑟琳·加拉格尔表示。“在我们与百时美施贵宝的合作中推进第二个领先候选药物，彰显了我们 RNA 递送平台的强大实力与多功能性，也为我们携手为面临巨大未满足需求的患者及其家庭带来创新疗法注入了持续动力。”

The payment is pursuant to Atrium's global licensing and research collaboration with Bristol Myers Squibb (BMS) focused on the discovery, development and commercialization of innovative RNA-based therapies for multiple cardiovascular indications.

该笔付款是根据Atrium与百时美施贵宝（BMS）达成的全球许可及研发合作协议进行的，该合作专注于针对多种心血管适应症的创新型RNA疗法的发现、开发和商业化。

Under the terms of the agreement, Atrium is eligible to receive up to approximately $1.35 billion in research and development milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales. BMS will fund all future clinical development, regulatory and commercialization activities coming from the collaboration..

根据协议条款，Atrium 有资格获得高达约 13.5 亿美元的研发里程碑付款、高达约 8.25 亿美元的商业化里程碑付款，以及基于净销售额的低至双位数百分比的分级特许权使用费。BMS 将资助因该合作而产生的所有未来临床开发、监管和商业化活动。

About Atrium Therapeutics

关于Atrium Therapeutics

Atrium Therapeutics, Inc. (Nasdaq:

Atrium Therapeutics, Inc.（纳斯达克：

RNA

核糖核酸

) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration's (FDA) recent clearance of its Investigational New Drug (IND) application for ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome, Atrium is advancing its first precision cardiology program into the clinic through the Corventis Phase 1/2 clinical trial.

）正在开创性地将核糖核酸（RNA）疗法靶向递送至心脏，以改变心肌病患者的护理标准。随着美国食品药品监督管理局（FDA）最近批准其针对PRKAG2（蛋白激酶AMP激活非催化亚基Gamma 2）综合征的ATR 1072的新药临床试验（IND）申请，Atrium公司正通过Corventis一期/二期临床试验将其首个精准心脏病学项目推进至临床阶段。

The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides, and is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA).

该公司的专有技术由Avidity Biosciences, Inc.设计，将单克隆抗体（mAbs）及其他靶向递送配体的组织选择性与寡核苷酸的精确性相结合，旨在通过小干扰RNA（siRNA）的靶向非病毒递送，选择性针对遗传性心脏疾病的根本驱动因素。

This approach builds upon learnings from demonstrated delivery to skeletal muscle and applies it for efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. Beyond ATR 1072, the Company's pipeline includes ATR 1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies..

该方法基于在骨骼肌递送方面已验证的经验，并将其应用于心脏的高效递送，有望克服与非特异性组织递送相关的挑战。除ATR 1072外，公司的产品管线还包括用于PLN（磷脂兰蛋白）心肌病的ATR 1086，以及两个针对罕见心肌病的未公开研究靶点。

For more information about our RNA delivery platform, development pipeline and people, please visit

欲了解更多关于我们RNA递送平台、研发管线及团队的信息，请访问

https://atriumtherapeutics.com/

https://atriumtherapeutics.com/

and engage with us on

并与我们互动

LinkedIn

领英

.

。

Availability of Other Information About Atrium Therapeutics

Atrium Therapeutics 其他信息的可用性

Investors and others should note that Atrium Therapeutics communicates with its investors and the public using its website

投资者及其他人士应注意，Atrium Therapeutics 通过其网站与投资者及公众进行沟通。

https://atriumtherapeutics.com/

https://atriumtherapeutics.com/

,

，

including, but not limited to, Atrium Therapeutics' disclosures, investor presentations and FAQs, Securities and Exchange Commission (SEC) filings, press releases, public conference call transcripts and webcast transcripts, as well as on LinkedIn. The information that Atrium Therapeutics posts on its website or on LinkedIn could be deemed to be material information.

包括但不限于 Atrium Therapeutics 的披露文件、投资者演示文稿和常见问题解答、美国证券交易委员会（SEC）备案文件、新闻稿、公开电话会议记录和网络直播文字记录，以及其在 LinkedIn 上发布的信息。Atrium Therapeutics 在其网站或 LinkedIn 上发布的信息可能被视为重大信息。

As a result, Atrium Therapeutics encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Atrium Therapeutics' website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended..

因此，Atrium Therapeutics 鼓励投资者、媒体及其他感兴趣的人士定期查阅其在该等平台发布的信息。Atrium Therapeutics 网站或社交媒体上的内容不得被视为通过引用方式纳入根据经修订的《1933年证券法》提交的任何文件中。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: Atrium's strategy, business plans and objectives; the strength, versatility and potential of Atrium's RNA delivery platform; the advancement, development and potential commercialization of programs under Atrium's collaboration with BMS; the potential for Atrium to receive future milestone payments and royalties under the collaboration with BMS; the ability of the collaboration with BMS to generate additional development candidates and novel therapies; the potential therapeutic benefits of RNA-based therapies; and the potential to address significant unmet medical needs for patients with cardiovascular diseases.

本新闻稿包含1995年《美国私人证券诉讼改革法》所定义的“前瞻性陈述”，包括但不限于以下方面的陈述：Atrium的战略、业务计划与目标；Atrium的RNA递送平台的优势、多功能性及潜力；Atrium与BMS合作下各项目的推进、开发及潜在商业化前景；Atrium在与BMS的合作中未来获得里程碑付款和特许权使用费的可能性；该合作产生额外候选药物及新型疗法的能力；基于RNA的疗法的潜在治疗益处；以及满足心血管疾病患者重大未满足医疗需求的潜力。

Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'may,' 'could,' 'would,' 'expect,' 'seek,' 'anticipate,' 'look forward,' 'believe,' 'committed,' 'continue,' 'intend,' or similar terms. You should not place undue reliance on these statements.

前瞻性陈述通常可以通过“潜在”、“能够”、“将”、“计划”、“可能”、“可以”、“会”、“预期”、“寻求”、“预计”、“展望”、“相信”、“承诺”、“继续”、“打算”等词语或类似术语来识别。您不应过度依赖这些陈述。

Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Particular areas where risks or uncertainties could cause Atrium's actual results to be materially different than those expressed in Atrium's forward-looking statements include but are not limited to: the initiation, timing, progress, potential registrational quality, and results of our research and development programs, preclinical studies, any clinical trials, and other regulatory submissions; the beneficial characteristics, including potential safety, efficacy and therapeutic effects of our p.

此类前瞻性陈述基于我们对未来事件的当前信念和预期，并受制于重大的已知和未知风险及不确定性。可能导致Atrium实际结果与其前瞻性陈述中表达的结果存在重大差异的风险或不确定性领域包括但不限于：我们的研发项目、临床前研究、任何临床试验以及其他监管申报的启动、时间安排、进展、潜在的注册质量及结果；我们产品的有益特性，包括潜在的安全性、有效性和治疗效果。

SOURCE Atrium Therapeutics

来源：Atrium Therapeutics

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示